The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial

References

• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Ardeshna K M, Smith P, Norton A, Hancock B W, Hoskin P J, Mclennan K A, , on behalf of the British National Lymphoma Investigation, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516–522
   PubMed Web of Science ®Google Scholar
• Lister T A, Cullen M H, Beard M E, Brearley R L, Whitehouse J M, Wrigley P F, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1978; 1: 533–537
   PubMed Web of Science ®Google Scholar
• Jones L, Cotter F E, Lord D, Newland A C. Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkin's lymphoma. Haem Onc 1990; 8: 41–45
   PubMed Web of Science ®Google Scholar
• Taylor P RA, Jackson G H, Galloway M J, Soukop M, Tinegate H, Angus B, Proctor S J. Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen; chlorambucil, idarubicin, dexamethasone (CID)—a phase II study. Cancer Chemother Pharmacol 2000; 46: 63–68
   PubMed Web of Science ®Google Scholar
• Rohatiner A, Radford J, Deakin D, Earl H, Love S B, Price O, Wilson A, Lister T A. Randomised controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001; 85: 29–35
   PubMed Web of Science ®Google Scholar
• Leonard R CF, Hayward R L, Prescott R J, Wang J X. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol 1991; 2: 655–663
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, Whire J, Armitage J O, Arranaz-Saez R, et al. Follicular Lymphoma International Prognostic Index (FLIPI). Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Stansfeld A G, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al. Updated Kiel classification for lymphomas. Lancet 1998; 49: 292–293
   Google Scholar
• Oken M M, Creech R H, Tormey D C, Horton J, Davies T E, McFadden G, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO handbook for reporting results of cancer treatment. World Health Organisation, Geneva 1979
   Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from The International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. JASA 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II Analysis and Examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cameron D A, Leonard R C, Mao J H, Prescott R J. Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Leuk Lymphoma 1993; 10: 89–99
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma on behalf of the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, Escoda L, Terol M J, Marin P, et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–1348
   PubMed Web of Science ®Google Scholar
• Federico M, Vitolo U, Zinzani P L, Chisesi T, Clo V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783–789
   PubMed Web of Science ®Google Scholar
• Nicolle A, Proctor S J, Summerfield G P. High dose chlorambucil in the treatment of lymphoid malignancies. Leuk Lymphoma 2004; 45: 271–275
   PubMed Web of Science ®Google Scholar
• Bernard T, Johnson S AN, Prentice A G, Jones L, Phillips M J, Newland A C. Mitoxantrone, Chlorambucil and Prednisolone in the treatment of non Hodgkin's lymphoma. Leuk Lymphoma 1994; 15: 481–485
   PubMed Web of Science ®Google Scholar
• Rohatiner A ZS, Gregory W M, Peterson B, Borden E, Solal-Seligny P, Hagenbeek A, et al. Met-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Hiddeman W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cycloposphmide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with CHOP alone: results of a prospective randomised study of the German Low Grade Lympoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Clin Oncol 1999; 17: 268–276
   Web of Science ®Google Scholar
• Jaeger G, Neumeister P, Brezinschek R, Hofler G, Quehenberger F, Linkesch W, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haem 2002; 69: 21–26
   PubMed Web of Science ®Google Scholar